In April, the Department of Health and Human Services published a proposed rule titled "HIPAA Privacy Rule to Support Reproductive Health Care Privacy." AMCP took the opportunity to submit comments and suggestions in support of the rule on June 16.
On May 12, CMS released new draft guidance on the Manufacturer Discount Program, enacted into law as part of the Inflation Reduction Act of 2022 (IRA). In response to the draft guidance, AMCP submitted comments on June 12. In the comment letter, AMCP urges CMS to continue to take precautions against potential unintended consequences throughout its implementation of the IRA.
The AMCP Format public comment period facilitates an exchange of information between manufacturers and health care decision-makers to inform formulary and coverage decisions.
May 2023 Legislative & Regulatory Briefing: AMCP’s Jennifer Mathieu Shares Tactics for Expanding Access to PDTs; ICYMI: Law CPE Sessions from AMCP 2023 Now Available on AMCP Learn; AMCP Submits Comments on Race and Ethnicity Statistical Standards; CMS Issues Final Medicare Part D DIR Reporting Guidance; Register Your Organization for the AMCP IRA Workshop Series.
On May 15, AMCP joined dozens of other health care organizations in a sign-on letter thanking the Biden Administration for relaunching the Cancer Moonshot program. First launched in 2016 with the mission to accelerate the rate of progress against cancer, the program's national goal is to reduce the death rate of cancer by at least 50% over the next 25 years. The letter applauds the program's prioritization of cancer prevention, especially though human papillomavirus (HPV) vaccination.
AMCP's volunteers are vital players in propelling our mission forward. In this installment of the AMCP Volunteer Spotlight, we are featuring Matt Moen, PharmD, MBA, AMCP Membership Committee member.
On April 27, AMCP submitted comments in response to the Office of Management and Budget's Initial Proposals for Updating Race and Ethnicity Standards. In the comment letter, AMCP provides several recommendations which align with the organization's strategic priority of Addressing Disparities in Medication Use and Access.